Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
85.6M
-
Number of holders
-
64
-
Total 13F shares, excl. options
-
39M
-
Shares change
-
+585K
-
Total reported value, excl. options
-
$120M
-
Value change
-
-$3.68M
-
Put/Call ratio
-
0.64
-
Number of buys
-
39
-
Number of sells
-
-29
-
Price
-
$3.13
Significant Holders of Larimar Therapeutics, Inc. - Common Stock (LRMR) as of Q2 2023
82 filings reported holding LRMR - Larimar Therapeutics, Inc. - Common Stock as of Q2 2023.
Larimar Therapeutics, Inc. - Common Stock (LRMR) has 64 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 39M shares
of 85.6M outstanding shares and own 45.58% of the company stock.
Largest 10 shareholders include DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (16.9M shares), CHI Advisors LLC (3.41M shares), Verition Fund Management LLC (2.72M shares), Woodline Partners LP (1.68M shares), JANUS HENDERSON GROUP PLC (1.45M shares), BlackRock Inc. (1.44M shares), VANGUARD GROUP INC (1.39M shares), Opaleye Management Inc. (1.39M shares), CITADEL ADVISORS LLC (1.18M shares), and Point72 Asset Management, L.P. (839K shares).
This table shows the top 64 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.